BACKGROUND/AIMS: The CD4(+) T cell subset lacking surface CD28 plays a role in atherosclerotic cardiovascular disease. The association between CD4(+)CD28(null) T cells and early atherosclerotic changes in chronic kidney disease (CKD) has never been investigated. We evaluated the frequency of circulating CD4(+)CD28(null) cells in 128 CKD and 62 control subjects. METHODS: Phenotype (CD4 and CD28) and cytotoxic potential (perforin and granzyme B expression) were studied by flow cytometry. Systemic inflammation (hsCRP, IL-6 and TNF-α) was analyzed by ELISA. Common carotid artery intima-media thickness (CCA-IMT) was measured with an ultrasound system. The effect of TNF-α and IL-6 on these cells was evaluated in vitro. RESULTS: The frequency of CD4(+)CD28(null) cells was significantly increased in CKD patients (10.14 ± 0.8 vs. 3.53 ± 0.36, p < 0.0001). The expression of perforin and granzyme B on CD4(+)CD28(null) cells was found to be significantly higher compared to CD4(+)CD28(+) cells (p < 0.0001). A larger proportion of CD4(+)CD28(null) cells obtained from CKD subjects showed the expression of perforin and granzyme B compared to those from healthy controls. CKD patients showed increased CCA-IMT (p < 0.0001). CD4(+)CD28(null) cells were positively correlated with the IMT (r = 0.505, p < 0.0001). CKD subjects showed increased levels of hsCRP, IL-6 and TNF-α. Only the TNF-α level showed a correlation with CD4(+)CD28(null) cells (r = 0.45, p < 0.0001). In vitro treatment with TNF-α but not IL-6 resulted in further downregulation of CD28 on the CD4(+) T cell surface. CONCLUSIONS: CKD subjects exhibit an increase in the circulating cytotoxic CD4(+)CD28(null) T lymphocyte population. CD4(+)CD28(null) cell expansion correlated with preclinical atherosclerotic changes. TNF-α shows a specific relationship and might have a role in the expansion of this subset in CKD.
BACKGROUND/AIMS: The CD4(+) T cell subset lacking surface CD28 plays a role in atherosclerotic cardiovascular disease. The association between CD4(+)CD28(null) T cells and early atherosclerotic changes in chronic kidney disease (CKD) has never been investigated. We evaluated the frequency of circulating CD4(+)CD28(null) cells in 128 CKD and 62 control subjects. METHODS: Phenotype (CD4 and CD28) and cytotoxic potential (perforin and granzyme B expression) were studied by flow cytometry. Systemic inflammation (hsCRP, IL-6 and TNF-α) was analyzed by ELISA. Common carotid artery intima-media thickness (CCA-IMT) was measured with an ultrasound system. The effect of TNF-α and IL-6 on these cells was evaluated in vitro. RESULTS: The frequency of CD4(+)CD28(null) cells was significantly increased in CKDpatients (10.14 ± 0.8 vs. 3.53 ± 0.36, p < 0.0001). The expression of perforin and granzyme B on CD4(+)CD28(null) cells was found to be significantly higher compared to CD4(+)CD28(+) cells (p < 0.0001). A larger proportion of CD4(+)CD28(null) cells obtained from CKD subjects showed the expression of perforin and granzyme B compared to those from healthy controls. CKDpatients showed increased CCA-IMT (p < 0.0001). CD4(+)CD28(null) cells were positively correlated with the IMT (r = 0.505, p < 0.0001). CKD subjects showed increased levels of hsCRP, IL-6 and TNF-α. Only the TNF-α level showed a correlation with CD4(+)CD28(null) cells (r = 0.45, p < 0.0001). In vitro treatment with TNF-α but not IL-6 resulted in further downregulation of CD28 on the CD4(+) T cell surface. CONCLUSIONS:CKD subjects exhibit an increase in the circulating cytotoxicCD4(+)CD28(null) T lymphocyte population. CD4(+)CD28(null) cell expansion correlated with preclinical atherosclerotic changes. TNF-α shows a specific relationship and might have a role in the expansion of this subset in CKD.
Authors: Dimitrios Chanouzas; Lovesh Dyall; Peter Nightingale; Charles Ferro; Paul Moss; Matthew David Morgan; Lorraine Harper Journal: Trials Date: 2016-07-22 Impact factor: 2.279